BACKGROUND: Cell senescence is implicated in numerous age-related conditions. Drugs and nutritional supplements developed for a variety of purposes kill senescent cells (senolytics) or suppress their secretions (senomorphics). There is interest in repurposing such drugs to treat or prevent age-related diseases. To date, only small-scale preliminary trials have been conducted. METHOD: At a workshop convened by the National Institute on Aging in August 2019, academic, industry, and government scientists reviewed issues for phase II trials of potentially repurposable drugs, or dietary supplements, to assess benefits and risks of their senolytic (killing senescent cells) or senomorphic (altering senescent cells' phenotypes) effects in treating or preventing age-related conditions. RESULTS: Participants reviewed mechanisms and effects of cellular senescence, senolytics, and senomorphics of several classes and their potential role in treating or preventing disease, modulators of the senescence-associated secretory phenotype, needs for senescence markers, data and specimen resources, infrastructure for planning trials, and potential effects on outcomes in older patients with multimorbidity and polypharmacy. CONCLUSIONS: Participants noted the importance of considering potential effects of candidate drugs on multiple aging outcomes. It is important to assess drugs' specificity for killing senescent cells and the balance between senolytic and cytotoxic effects. Markers of specific senescent cell types are needed to assess intervention responses. There are potential interactions with coexisting diseases and their treatments in older persons. Standardized measures could enhance comparisons and pooling of data. Additional characterization of human cell senescent phenotypes is needed for developing better and more specific senolytics and senomorphics. Published by Oxford University Press on behalf of The Gerontological Society of America 2021.
BACKGROUND: Cell senescence is implicated in numerous age-related conditions. Drugs and nutritional supplements developed for a variety of purposes kill senescent cells (senolytics) or suppress their secretions (senomorphics). There is interest in repurposing such drugs to treat or prevent age-related diseases. To date, only small-scale preliminary trials have been conducted. METHOD: At a workshop convened by the National Institute on Aging in August 2019, academic, industry, and government scientists reviewed issues for phase II trials of potentially repurposable drugs, or dietary supplements, to assess benefits and risks of their senolytic (killing senescent cells) or senomorphic (altering senescent cells' phenotypes) effects in treating or preventing age-related conditions. RESULTS: Participants reviewed mechanisms and effects of cellular senescence, senolytics, and senomorphics of several classes and their potential role in treating or preventing disease, modulators of the senescence-associated secretory phenotype, needs for senescence markers, data and specimen resources, infrastructure for planning trials, and potential effects on outcomes in older patients with multimorbidity and polypharmacy. CONCLUSIONS: Participants noted the importance of considering potential effects of candidate drugs on multiple aging outcomes. It is important to assess drugs' specificity for killing senescent cells and the balance between senolytic and cytotoxic effects. Markers of specific senescent cell types are needed to assess intervention responses. There are potential interactions with coexisting diseases and their treatments in older persons. Standardized measures could enhance comparisons and pooling of data. Additional characterization of human cell senescent phenotypes is needed for developing better and more specific senolytics and senomorphics. Published by Oxford University Press on behalf of The Gerontological Society of America 2021.
Authors: Giovanna Speranza; Larry Anderson; Alice P Chen; Khanh Do; Michelle Eugeni; Marcie Weil; Larry Rubinstein; Eva Majerova; Jerry Collins; Yvonne Horneffer; Lamin Juwara; Jennifer Zlott; Rachel Bishop; Barbara A Conley; Howard Streicher; Joseph Tomaszewski; James H Doroshow; Shivaani Kummar Journal: Invest New Drugs Date: 2017-08-12 Impact factor: 3.850
Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Alejandra Hernandez-Segura; Tristan V de Jong; Simon Melov; Victor Guryev; Judith Campisi; Marco Demaria Journal: Curr Biol Date: 2017-08-30 Impact factor: 10.834
Authors: Remi-Martin Laberge; Yu Sun; Arturo V Orjalo; Christopher K Patil; Adam Freund; Lili Zhou; Samuel C Curran; Albert R Davalos; Kathleen A Wilson-Edell; Su Liu; Chandani Limbad; Marco Demaria; Patrick Li; Gene B Hubbard; Yuji Ikeno; Martin Javors; Pierre-Yves Desprez; Christopher C Benz; Pankaj Kapahi; Peter S Nelson; Judith Campisi Journal: Nat Cell Biol Date: 2015-07-06 Impact factor: 28.824
Authors: Vassilis Gorgoulis; Peter D Adams; Andrea Alimonti; Dorothy C Bennett; Oliver Bischof; Cleo Bishop; Judith Campisi; Manuel Collado; Konstantinos Evangelou; Gerardo Ferbeyre; Jesús Gil; Eiji Hara; Valery Krizhanovsky; Diana Jurk; Andrea B Maier; Masashi Narita; Laura Niedernhofer; João F Passos; Paul D Robbins; Clemens A Schmitt; John Sedivy; Konstantinos Vougas; Thomas von Zglinicki; Daohong Zhou; Manuel Serrano; Marco Demaria Journal: Cell Date: 2019-10-31 Impact factor: 41.582
Authors: Geoffrey I Shapiro; Eunice Kwak; Bruce J Dezube; Murray Yule; John Ayrton; John Lyons; Daruka Mahadevan Journal: Clin Cancer Res Date: 2014-10-21 Impact factor: 12.531
Authors: Peisu Zhang; Yuki Kishimoto; Ioannis Grammatikakis; Kamalvishnu Gottimukkala; Roy G Cutler; Shiliang Zhang; Kotb Abdelmohsen; Vilhelm A Bohr; Jyoti Misra Sen; Myriam Gorospe; Mark P Mattson Journal: Nat Neurosci Date: 2019-04-01 Impact factor: 24.884
Authors: Marissa J Schafer; Thomas A White; Koji Iijima; Andrew J Haak; Giovanni Ligresti; Elizabeth J Atkinson; Ann L Oberg; Jodie Birch; Hanna Salmonowicz; Yi Zhu; Daniel L Mazula; Robert W Brooks; Heike Fuhrmann-Stroissnigg; Tamar Pirtskhalava; Y S Prakash; Tamara Tchkonia; Paul D Robbins; Marie Christine Aubry; João F Passos; James L Kirkland; Daniel J Tschumperlin; Hirohito Kita; Nathan K LeBrasseur Journal: Nat Commun Date: 2017-02-23 Impact factor: 14.919
Authors: Sonja Suvakov; Hajrunisa Cubro; Wendy M White; Yvonne S Butler Tobah; Tracey L Weissgerber; Kyra L Jordan; Xiang Y Zhu; John R Woollard; Fouad T Chebib; Natasa M Milic; Joseph P Grande; Ming Xu; Tamara Tchkonia; James L Kirkland; Lilach O Lerman; Vesna D Garovic Journal: Biol Sex Differ Date: 2019-09-14 Impact factor: 5.027
Authors: Sean J Miller; Cameron E Campbell; Helen A Jimenez-Corea; Guan-Hui Wu; Robert Logan Journal: Front Neurosci Date: 2022-04-19 Impact factor: 5.152